anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Diabetes mellitus (DM) is a worldwide pandemic affecting 500 million people. It is known to be associated with increased susceptibility to soft tissue infections (STI). Despite being a major public health burden, the literature relating the effects of DM and the presentation, severity and healing of STIs in general surgical patients remain limited.
METHOD: We conducted a retrospective review of all patients admitted with STI in a tertiary teaching hospital over a 12-month period. Patient demographics and surgical outcomes were collected and analysed.
RESULTS: During the study period, 1059 patients were admitted for STIs (88% required surgery). DM was an independent risk factor for LOS. Diabetic patients presented with higher body-mass index (28 vs. 26), larger abscess size (24 vs. 14 cm2) and had a longer length of stay (4.4 days vs. 2.9 days). They also underwent a higher proportion of wide debridement and application of negative pressure wound therapy (42% vs. 35%). More diabetic patients underwent subsequent re-operation within the same sitting (8 vs. 4). Diabetic patients were two times more likely to present with carbuncles (p = 0.02).
CONCLUSION: The incidence of STIs among DM patients represent a significant disease burden, surgeons should consider intensive patient counselling and partnering with primary care providers in order to help reduce the incidence of future STI admissions based upon lifestyle modification and glucose control.
The invention relates to a monohydroxycamptothecin glutarate medicine composition. The monohydroxycamptothecin glutarate can be prepared by subjecting hydroxycamptothecin and glutaric anhydride to acetylation. Activity tests show that the monohydroxycamptothecin glutarate designed and synthesized in the invention is a proper antitumor candidate medicine, especially a candidate medicine for treating breast cancer, liver cancer, colon cancer, gastric cancer and lung cancer. Compared with a positive control medicine that is camptothecin, water solubility and stability are improved. A synthesizing method of the monohydroxycamptothecin glutarate is simple, easily available in raw materials, high in yield of the synthesis route, and easy to operate and implement. The monohydroxycamptothecin glutarate has a wide prospect in the field of development and application of antitumor medicines.
Introduction: Renal colic is frequently treated with opioids; however, narcotic analgesic use can lead to dependence and abuse. We evaluated use trends of opioids and nonsteroidal anti-inflammatory drugs (NSAIDs) for pain management of kidney stones in United States emergency departments (EDs) from 2015 to 2021. Methods: Kidney stone encounters were identified using National Hospital Ambulatory Medical Care Survey data. We applied a multistage survey weighting procedure to account for selection probability, nonresponse, and population weights. Medication use trends were estimated through logistic regressions on the timing of the encounter, adjusted for selected demographic and clinical characteristics. Results: Between 2015 and 2021, there were an estimated 9,433,291 kidney stone encounters in United States EDs. Opioid use decreased significantly (annual odds ratio [OR]: 0.87, p = 0.003), and there was no significant trend in NSAID use. At discharge, male patients were more likely than females (OR: 1.93, p = 0.001) to receive opioids, and Black patients were less likely than White patients (OR: 0.34, p = 0.010) to receive opioids. Regional variation was also observed, with higher odds of discharge prescriptions in the West (OR: 3.15, p = 0.003) and Midwest (OR: 2.49, p = 0.010), compared with the Northeast. Thirty-five percent of patients received opioids that were stronger than morphine. Conclusion: These results suggest improved opioid stewardship from ED physicians in response to the national opioid epidemic. However, regional variation as well as disparities in discharge prescriptions for Black and female patients underscore opportunities for continued efforts.
FIELD: medicine. ^ SUBSTANCE: preliminarily adjoining in wound bottom cortical plate is drilled by means of 2.0-2.5 mm drill with 2 holes per 1 cm2 until blood dew appears. On wound surface applied is CollapAn gel. As cracks appear in hardened CollapAn coating in process of defect healing, they are filled with CollapAn gel. ^ EFFECT: invention makes it possible to restore soft tissue coating even if blood circulation at the wound bottom is disturbed. ^ 1 ex
This invention is concerned with odor control animal shampoo. Odor control animal shampoos in accordance with this invention comprises a shampoo base to which is added a halo sulfonamide compound. In use the halo sulfonamide compound, as is contained in the shampoo, reacts with odorous nitrogen and sulfur bearing compounds which are contained on the body of a pet. The halo sulfonamide compound reacts with the nitrogen and sulfur compounds to reduce these compounds to a non odorous format. The animal shampoo of this invention are particularly effective in controlling odors which originate on dogs and cats. The halo sulfonamide compound can be present in the shampoo formulation at any at any effective concentrations. Shampoo formulations which incorporate from about 0.1 to about 5.0 weight percent of a halo sulfonamide compound have been found to be effective. Chloramine-T is a preferred sulfonamide compound for use as an odor control agent in the shampoo formulations of this invention.
The present disclosure provides methods, systems, and devices for coregistering imaging data to form three-dimensional superimposed images of a biological target such as a wound, a tumor, or a surgical bed. A three-dimensional map can be generated by projecting infrared radiation at a target area, receiving reflected infrared radiation, and measuring depth of the target area. A three-dimensional white light image can be created from a captured two-dimensional white light image and the three-dimensional map. A three-dimensional fluorescence image can be created from a captured two-dimensional fluorescence image and the three-dimensional map. The three-dimensional white light image and the three-dimensional fluorescence image can be aligned using one or more fiducial markers to form a three-dimensional superimposed image. The superimposed image can be used to track wound healing and to excise cancerous tissues, for example, breast tumors. Images can be in the form of videos.
Edaravone dexborneol (ED) is a novel neuroprotective compound that consists of two active ingredients, edaravone and ( +)-borneol in a 4:1 ratio, which has been shown the anti-inflammatory properties in animal models of ischemic stroke, cerebral hemorrhage, and autoimmune encephalomyelitis. However, the effect of ED on the polarization of microglia in neuroinflammation has not been elucidated. This study was to investigate the effects of ED on the polarization of microglia induced by lipopolysaccharide (LPS) and potential mechanisms. BV-2 microglial cells were incubated with ED (100, 200, and 400 µM) for 2 h, followed by lipopolysaccharide (LPS, 1 µg/ml) for 12 h. The researchers used the Griess method, western blot, immunocytochemistry, and subcellular fractionation to assess the effects and potential mechanisms of ED on neuroinflammatory reactions. The expression of ROS and the activities of antioxidant enzymes (SOD, GPx, and CAT) in LPS-induced BV-2 cells were also measured using the DCFH-DA fluorescent probe and colorimetric methods, respectively. It was observed that ED significantly declined the levels of TLR4/NF-κB pathway-associated proteins (TLR4, MyD88, p65, p-p65, IκBα, p-IκBα, IKKβ, p-IKKβ) and therefore inhibited LPS-induced production of NO, IL-1β, and TNF-α. Moreover, ED markedly downregulated the M1 marker (iNOS) and upregulated the M2 marker (Arginase-1, Ym-1). In addition, ED also reduced ROS generation and enhanced GPx activity. ED induced the polarization of LPS-stimulated microglia from M1 to M2 against inflammation by negatively regulating the TLR4/MyD88/NF-κB signaling pathway. Additionally, ED performed antioxidative function by depleting the intracellular excessive ROS caused by LPS through the enhancement of the enzymatic activity of GPx. ED may be a potential agent to attenuate neuroinflammation via regulating the polarization of microglia.
OBJECTIVE: The aim of the study is to describe cost and frequency of work-related musculoskeletal disorders in Kansas.
METHODS: Data were provided by the Kansas Department of Labor and included all closed workers' compensation claims entailing indemnity and medical costs from 2014 to 2022.
RESULTS: Work-related musculoskeletal disorder claims entailed a median total cost of $20,097. Medical comprised 48.4% of costs, indemnity 46.4%, and legal 5.2%. The most frequently injured and costliest body part was the shoulder. Manufacturing comprised 28.4% of claims, followed by health care and office. Lifting was the most common cause, generating 32.0% of claims. Education, transportation, and mining were among industries with above average claim rates.
CONCLUSIONS: Very few studies use workers' compensation data to assess work-related musculoskeletal disorder costs. This study introduces a state not yet analyzed and presents more recent years of data than available in the literature.
PCT No. PCT/AU90/00373 Sec. 371 Date Jun. 25, 1991 Sec. 102(e) Date Jun. 25, 1991 PCT Filed Aug. 24, 1990 PCT Pub. No. WO91/02799 PCT Pub. Date Mar. 7, 1991.This invention relates to the preparation of novel fusion proteins which comprise an analogue of LHRH and TraTp or an analogue of TraTp. The fusion proteins of the invention are useful as components of vaccines for the inhibition or control of reproductive functions in vertebrate hosts. The invention also relates to polynucleotide molecules encoding the fusion proteins, to transformant hosts expressing the fusion proteins and to methods of inhibiting or controlling reproductive function in vertebrate hosts using the fusion proteins or vaccines of the invention.
Participants received a dose of 35 milligrams per meter square (mg/m\^2) of TAS-102 tablets orally twice per day (BID) within 1 hour after completion of morning and evening meals, in 4-week cycle. In each 4-week cycle, TAS-102 was administered for 2 weeks, as 5 days a week with 2 days rest, followed by a 14-day rest. Also participants received 3 milligrams per kilogram per dose (mg/kg/dose) Nivolumab intravenous (I.V) infusion over 60 minutes every 14 days (on Day 1 and Day 15 of each 4-week cycle).
An ultasound guided SMNB is admitted on one half of the patients face (left or right) according to randomiced allocation. 0.15 ml/kg of bupivacaine 0.25 mg/ml with epinephrin 5 mcg/ml is injected.
The invention discloses a cationic polymer for co-loading drugs and genes and application thereof. Constructed cation PCL- ss ‑P(GHA‑ co PEGMA) polymer is rich in side chain, so that the polymer has good biocompatibility and water solubility; in addition, the shell layer is rich in hydroxyl groups, so that transmembrane transport of a drug/gene complex can be promoted, and transcription and expression of genes in cells can be improved. Under the condition of higher glutathione, the main chain in the drug/gene complex is cracked, and the drug in the polymer micelle is released, thereby achieving the purpose of inhibiting the proliferation of tumor cells. The release of the medicine and the transcription and expression of the gene can be combined to treat the lung cancer, and effectively overcome the drug resistance of the anticancer medicine in cells. The method has the advantages of mild experimental conditions, easy control of the structure of the cationic polymer, simple operation, easily obtained raw materials, easy purification and suitability forIndustrial production. Therefore, the recombinant plasmid can be used as a co-vector of an anti-cancer drug and a cancer suppressor gene and has a larger market application prospect in the future.
Participants will receive standardized 9.25g stick packs of placebo. The study participants will take one of these stick packs dissolved in water three times a day (morning, noon, and evening) for 8 weeks.
In patients with drug-resistant epilepsy, electrical stimulation of the brain in response to epileptiform activity can make seizures less frequent and debilitating. This therapy, known as closed-loop responsive neurostimulation (RNS), aims to directly halt seizure activity via targeted stimulation of a burgeoning seizure. Rather than immediately stopping seizures as they start, many RNS implants produce slower, long-lasting changes in brain dynamics that better predict clinical outcomes. Here we hypothesize that stimulation during brain states with less epileptiform activity drives long-term changes that restore healthy brain networks. To test this, we quantified stimulation episodes during low- and high-risk brain states-that is, stimulation during periods with a lower or higher risk of generating epileptiform activity-in a cohort of 40 patients treated with RNS. More frequent stimulation in tonic low-risk states and out of rhythmic high-risk states predicted seizure reduction. Additionally, stimulation events were more likely to be phase-locked to prolonged episodes of abnormal activity for intermediate and poor responders when compared to super-responders, consistent with the hypothesis that improved outcomes are driven by stimulation during low-risk states. These results support the hypothesis that stimulation during low-risk periods might underlie the mechanisms of RNS, suggesting a relationship between temporal patterns of neuromodulation and plasticity that facilitates long-term seizure reduction.
One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The equipment to be used for NMES is VitalStim®. VitalStim is a product of Empi®. VitalStim® therapy involves the placement of electrodes to the muscles of the throat that is attached to a device that provides electrical stimulation. The intensity will be increased according to the subject's tolerance and when a "therapeutic" level is reached. Signs of reaching therapeutic level include changes in audible quality of swallows, triggers of swallows, and changes in quality of voice. This therapy is to be performed by a VitalStim® certified practitioner.
The study is using a randomized double-blind, parallel-group, placebo-controlled design. 30 patients per treatment group will be included into the study and randomized to the treatment groups using a computer program. Psychotic features of depression will be excluded by a score of 2 or less in the PANSS subscales P1, P3 and P6. Treatment resistance as defined by history of non-response to two antidepressants from different classes at an acceptable dose and period is confirmed retrospectively. If possible, treatment compliance should be confirmed by plasma level examination. After informed consent, visit 1 is performed on day 0 (inclusion criteria, history, demographics, physical examination, vital signs, HAMD, MADRS, CGI, lab). Study medication is started on day 1, the antidepressive therapy is continued at stable dose until the end of the study. Patients will receive a double-blind therapy of either 10 mg/d olanzapine or placebo. Study visits will be performed on days 4, 7, and 14 (visits 2-4: vital signs, HAMD, MADRS, CGI, lab).

After 14 days, the patients will be classified as responders or non-responders. A responder is defined by a reduction of the initial HAM-D score of more than 50%. Study treatment will be stopped in non-responders and continued in a double-blind manner in responders for further 60 days. Thereafter, the the study medication is stopped and the patients are observed for further 14 days. Study visits will be performed every 14 days. This extension phase was added to examine if a prolonged treatment with olanzapine could ensure a sustained treatment effect. It should be excluded that olanzapine has a short-term tranquillizer-like effect or leads to unfavourable medium- to-long-term depressiogenic effects as observed with other neuroleptics used in depression ( e.g. fluspirilene). Moreover, withdrawal effects should be excluded.
High protein diet predominantly provided from lean beef (one 3-oz portion per day; total beef intake 24 oz/week). The energy content of the additional protein foods will be isocalorically offset by substitution for low-protein foods.
Embodiments of this invention include systems and methods for developing individualized dietary and health improvement plans based on an individual's intestinal microbiome and digestive activity. More particularly, the invention is related to a system providing a hydrogen and/or methane sensor device and a wireless platform in communication with the sensor device to periodically analyze the individual's metabolic activity in correlation with their gut microbiome and a personal database to provide personalized feedback to the individual of treatment plans and general techniques that can be used to improve the individual's general health and well being. The systems and methods further include a system for analyzing the hydrogen and/or methane levels in the individual's exhalations or flatulence in light of the individual's intestinal microbiome. This analysis uses bioinformatics to relate alterations in hydrogen and/or methane levels to the individual's intestinal microbiome and personal diet and tolerances/intolerances to identify and communicate real time dietary suggestions and general dietary and health treatment plans. The relationship of the bioinformatics and alterations in hydrogen and/or methane levels is also used to infer drug effectiveness. Such general dietary guidance, health treatment plans, and drug effectiveness contribute to an overall improvement in a person's general health and well being.
PROBLEM TO BE SOLVED: To prepare a cosmetic having excellent applicability and safety, free from blotting in application and useful as a lipstick, etc. SOLUTION: The objective cosmetic is produced by using a fluid oil component (e.g. liquid paraffin) and a solid oil component (e.g. ceresin wax) and adjusting the I.O.B (inorganic value/organic value) difference between the fluid oil component and the solid oil component to preferably <=0.10 and the hardness of the mixture of both oil components to >=12. The solid oil component preferably has an I.O.B of 0-0.15. The cosmetic preferably contains a powder (e.g. talc).
In Latin America, obesity rates are among the highest in the world. Currently, people with obesity (PWO) receive suboptimal care due to several challenges and barriers. The international ACTION-IO study aimed to identify perceptions, attitudes and behaviours of PWO and healthcare providers (HCP), and to assess potential barriers to effective obesity care. The aim of this subanalysis of the Chilean cohort was to compare their characteristics, perceptions, attitudes and behaviours according to the percentage of weight loss (lower weight loss [LWL; ≤10%] or higher weight loss [HWL; >10%] of basal weight). The ACTION-IO survey was completed by 1000 Chilean PWO and 200 HCPs. Mean age of PWO was 38 years (range 18-75); 62% were female. The majority had class I obesity. HWL subgroup represented 17.2% of all Chilean subset. Specific characteristics of patients with HWL were identified (higher educational level, lower proportion of class III obesity, preference for consulting obesity specialists, considering conversations with HCP as very helpful). HWL patients reported higher rates of favourable outcomes following HCP advice and a higher probability of attending scheduled follow-up visits. Certain demographic and behavioural variables (educational level, consultation to obesity specialists, adherence to HCP advice, follow-up scheduled visits and becoming aware of the obesity state) may identify PWO with a higher probability of a greater weight loss.
PURPOSE:To obtain an X-ray contrast composition for digestive tracts, having high safety, easily swallowable and giving a clear X-ray image in contrast with conventional contrast agent composed of barium or iodine compound. CONSTITUTION:The contrast composition for digestive tracts for radiography is composed of a component containing nonmetallic elements having atomic number of <=8 (e.g. H, C, O and N) as main constituent elements. The composition is preferably produced by compounding 1-99% carbohydrates and 99-1% proteins in such a manner as to get a composition having a lipid content of <=0.5% and a density of 1.10-1.30g/cm<3>. The carbohydrate and the protein may be pure substances or a food rich in those substances, e.g. a food rich in carbohydrate (e.g. honey, starch syrup, reduced oligosaccharide, starch, sweet potato, potato and fruit) or a food rich in protein (e.g. kwalk, fresh cheese, various cheeses, defatted milk and concentrated whey protein).
The invention relates to a peach blossom lilac mask. The mask is characterized by comprising the following steps: 1) picking peach blossoms to be bloomed and Chinese wax gourd seeds (100g of fresh products or 30g of dried products), and pounding the peach blossoms to be bloomed and the Chinese wax gourd seeds together into mash; 2) grinding white lilacs into powder, and then mixing the powder and white honey into the peach blossom and Chinese wax gourd seed mash to obtain the mask; 3) applying the mask onto a face in the morning and evening, and washing the mask with clean water after 20-30 minutes. The mask has the effects of removing acne and eliminating black spots. Multiple vitamins and microelements contained in the peach blossoms can prevent melanin from being slowly deposited in skin, and can also effectively prevent the skin from being dry, rough and the like. The mask has the functions of promoting blood circulation, removing blood stasis and eliminating the black spots. The Chinese wax gourd seeds enable the skin to be whitened and remove black-yellow pigment, the white lilacs have the functions of killing bacteria, diminishing the inflammation, nourishing the skin, removing the toxicity and dispersing the swelling, and the honey can nourish the skin, diminish the inflammation and resist bacteria, so that the mask has significant effects of whitening the skin and diminishing the inflammation.
Leaf rust caused by the pathogen Puccinia triticina (Pt) is a destructive fungal disease of wheat that occurs in almost all wheat-growing areas across the globe. Genetic resistance has proven to be the best solution to mitigate the disease. Wheat breeders are continuously seeking new diversified and durable sources of resistance to use in developing new varieties. We developed recombinant inbred line (RIL) populations from two leaf rust-resistant genotypes (Kenya Kudu and AUS12568) introduced from Kenya to identify and characterize resistance to Pt and to develop markers linked closely to the resistance that was found. Our studies detected four QTL conferring adult plant resistance (APR) to leaf rust. Two of these loci are associated with known genes, Lr46 and Lr68, residing on chromosomes 1B and 7B, respectively. The remaining two, QLrKK_2B and QLrAus12568_5A, contributed by Kenya Kudu and AUS12568 respectively, are putatively new loci for Pt resistance. Both QLrKK_2B and QLrAus12568_5A were found to interact additively with Lr46 in significantly reducing the disease severity at adult plant growth stages in the field. We further developed a suite of six closely linked markers within the QLrAus12568_5A locus and four within the QLrKK_2B region. Among these, markers sunKASP_522 and sunKASP_524, flanking QLrAus12568_5A, and sunKASP_536, distal to QLrKK_2B, were identified as the most closely linked and reliable for marker-assisted selection. The markers were validated on a selection of 64 Australian wheat varieties and found to be polymorphic and robust, allowing for clear allelic discrimination. The identified new loci and linked molecular markers will enable rapid adoption by breeders in developing wheat varieties carrying diversified and durable resistance to leaf rust.